Those with preserved EF seemed to get more protection against HF events/CV death than those with reduced or unknown EF.

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

It’s a known problem, but treatment hasn’t improved in 20 years. Experts say it’s time for protocolized systems of care, they ...

Neither stenting nor endarterectomy provided a boost versus medical therapy alone in patients with asymptomatic stenosis.

The procurement and perfusion method, areas that are rapidly evolving, will likely play a role in the success of DCD transplants.

The mechanism remains unclear, but GLP-1 users had less MACE, CV death, and all-cause death driven by fewer amputations.

Though recombinant factor VIIa didn’t improve outcomes overall, treating very early and in those with a spot sign on CT may help.

A bundle of protocols including patient education, skin prep, and glove changes reduced infections at a large US surgical ...

Overcoming clinical inertia around starting and intensifying antihypertensive drugs is key, a researcher says.

Observational data point to the scope of opportunity that lies in GLP-1 drugs, SGLT2 inhibitors, and nonsteroidal MRAs.

Transparency is needed to improve equity, though it can be awkward to talk about salary, says Thomas MacGillivray.

Topics spanned from GLP-1s to aorto-coronary bypass without surgery, Lp(a)’s extended reach, US dietary guidelines, and more.